Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency
- 18 décembre 2024 - 1 mn de lecture
This is an extension study to Tercica study MS301 (NCT00125164) and is intended to collect long term safety and efficacy data on the continued use of recombinant human insulin-like growth factor-1 (rh IGF-1) in children and adolescents treated for primary IGF-1 deficiency (IGFD). The secondary objective is to use the data collected to learn more about the relationship of IGF-1 exposure to the promotion of normal growth and pubertal development.
18 décembre 2024
1 mn de lecture
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
18 décembre 2024
1 mn de lecture
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
18 décembre 2024
1 mn de lecture
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
18 décembre 2024
1 mn de lecture
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
18 décembre 2024
1 mn de lecture
Dysport® Adult Lower Limb Spasticity Follow-on Study
18 décembre 2024
1 mn de lecture
Dysport® Pediatric Lower Limb Spasticity Study
18 décembre 2024
1 mn de lecture
Dysport® Adult Lower Limb Spasticity Study
18 décembre 2024
1 mn de lecture
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
18 décembre 2024
1 mn de lecture
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
18 décembre 2024
1 mn de lecture